Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
The identification of succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) mutations in human cancers has rekindled the idea that altered cellular metabolism can transform cells. Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradation. Inappropriate HIF activation is suspected of contributing to the pathogenesis of SDH-defective and FH-defective tumours but can suppress tumour growth in some other contexts. IDH1 and IDH2, which catalyse the interconversion of isocitrate and 2-OG, are frequently mutated in human brain tumours and leukaemias. The resulting mutants have the neomorphic ability to convert 2-OG to the (R)-enantiomer of 2-hydroxyglutarate ((R)-2HG). Here we show that (R)-2HG, but not (S)-2HG, stimulates EGLN activity, leading to diminished HIF levels, which enhances the proliferation and soft agar growth of human astrocytes. These findings define an enantiomer-specific mechanism by which the (R)-2HG that accumulates in IDH mutant brain tumours promotes transformation and provide a justification for exploring EGLN inhibition as a potential treatment strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Insulator dysfunction may also be accompanied by promoter silencing events28,29, and by alterations to other pathways affected by 2-HG7,30.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [30]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“(R)-2HG competitively inhibited BCAT1, which is a cytosolic enzyme, with respect to 2OG over a physiologically-relevant range of 2OG concentrations”
From Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma (2018) · cites this paper as Koivunen et al., 2012
Experimental — accuracy not yet measuredIn the citing paper
“Though it is found at low levels in normal cells, D-2HG can accumulate to millimolar levels in cancer cells expressing mutant IDH. At these high concentrations, D-2HG can inhibit αKG-dependent dioxygenases, including enzymes involved in histone and DNA demethylation (Chowdhury et al., 2011; Janke et al., 2017; Koivunen et al., 2012; Xu et al., 2011).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Koivunen et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · cited 1×
“Consistent with recent reports, we found that both ( R )-2HG and ( S )-2HG inhibit a number of 2-OG-dependent enzymes in vitro”
BackgroundFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · cited 1×
“Consistent with recent reports, we found that both ( R )-2HG and ( S )-2HG inhibit a number of 2-OG-dependent enzymes in vitro”
BackgroundRole of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502 · cited 1×
“Although HIF is typically viewed as an oncoprotein it can behave as a tumour suppressor in embryonic stem cell”
BackgroundHypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380 · cited 1×
“Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradatio”
BackgroundIto, S., D’Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,373 · cited 1×
“Human EGLN1, 2 and 3, collagen P4H-I and FIH, and murine Tet1 and Tet2 were produced in insect cells and purified as described earlie”
MethodAbsolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli
Bennett, B. D., Kimball, E. H., Gao, M., Osterhout, R., Van Dien, S. J., & Rabinowitz, J. D. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.186 · Cited by 1,830 · cited 1×
“Studies in model organisms suggest that many metabolic enzymes are saturated in vivo with a mixture of substrate and competitive inhibitors and thus are sensitive to changes in substrate concentrations that are far above their nominal K m value”
BackgroundGlioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119 · cited 1×
“Nor are our data incompatible with the finding that HIF-1a protein levels are increased in IDH mutant tumours relative to normal brai”
ResultThe oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035
Cited by
Items 601–700 of 752
Wang, X., Shojaie, A., Zhang, Y., Shelley, D., Lampe, P. D., Levy, L., Peters, U., Potter, J. D., White, E., & Lampe, J. W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178444 · Cited by 5
The Immunobiology of Cancer: An Update Review
Meiliana, A., Dewi, N. M., & Wijaya, A. (2017) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v9i2.342 · Cited by 6
“More recently, cancer-associated isocitrate dehydrogenase (IDH)1 and IDH2 mutations were shown to generate an oncometabolite, known as 2-hydroxyglutarate (60,61), which regulates DNA (hyper)methylation (62,63), histone demethylation (64) and oxygen-sensing enzymes (65).”
BackgroundArteriovenous malformation within an isocitrate dehydrogenase 1 mutated anaplastic oligodendroglioma
Chen, C., Lai, G. P., Muller, K., & Carter, B. (2015) · Surgical Neurology International · doi:10.4103/2152-7806.159373 · Cited by 5
“However, another study reported that the accumulation of 2HG in IDH1 mutated cells activated an enzyme that degrades HIF‐1 and leads to decreased VEGF expression.[11] In the context of the current understanding of molecular AVM pathogenesis, the co‐occurrence of an AVM and an IDH1 mutated anaplastic oligodendroglioma…”
BackgroundCancer Therapies Targeting Cellular Metabolism
Morris, B. L., & Gutiérrez, A. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041657 · Cited by 6
Prickle4 Drives Microenvironmental Remodeling and Resistance to Parp Inhibition in IDH‐Mutant Glioma
Yang, J., Yang, H., Yuan, Y., Zhang, C., Fu, Z., Chen, Y., Xiong, Y., Chen, S., Ling, K., Liu, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202503866 · Cited by 5
Hubert, C. G., Read, R. D., Miller, T. E., Kim, U., Wang, X., Ishan, M., Wang, Z., Miller, E., Sun, Y. Y., Lai, A., et al. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag085 · Cited by 5
2-Oxoglutarate-dependent dioxygenases as oxygen sensors: their importance in health and disease
Lee, P. W. T., Kobayashi, M., Dohkai, T., Takahashi, I., Yoshida, T., & Harada, H. (2024) · The Journal of Biochemistry · doi:10.1093/jb/mvae087 · Cited by 5
Pineau, D., Garcia, L., Arnold, H., Hanžek, A., Arrieta, M., Gauthier, L., Granotier-Beckers, C., Boussin, F. D., Herbet, A., Hautière, M., et al. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70223 · Cited by 4
“Oli-godendroglioma cell lines included BT138, BT237 [52], BT054, and BT088 [53,54].”
Barekatain, Y., Yan, V. C., Arthur, K., Ackroyd, J. J., Khadka, S., de Groot, J., Huse, J. T., & Müller, F. L. (2020) · Communications Biology · doi:10.1038/s42003-020-1055-5 · Cited by 4
Park, Y. W., Han, K., Jang, G., Cho, M., Kim, S. B., Kim, H., Shin, N., Chang, J. H., Kim, S. H., Lee, S., et al. (2025) · European Radiology · doi:10.1007/s00330-025-11704-z · Cited by 4
“D-2-HG also promotes diminished hypoxia-inducible factor-1 alpha (HIF α ) levels [12].”
Self-citationEstablishing a Robust Molecular Taxonomy for Diffuse Gliomas of Adulthood
Huse, J. T. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.04.005 · Cited by 5
Wiehle, L., Raddatz, G., Pusch, S., Gutekunst, J., von Deimling, A., Rodríguez‐Paredes, M., & Lyko, F. (2017) · Cell Stress · doi:10.15698/cst2017.10.106 · Cited by 6
“D-2-HG produced by mIDH enzymes has been shown to inhibit the hydroxylation activity of α-ketoglutarate dependent dioxygenases, including the TET enzymes [3, 4].”
Immunometabolic Regulation of Anti-Tumor T-Cell Responses by the Oncometabolite D-2-Hydroxyglutarate
Böttcher, M., & Mougiakakos, D. (2019) · Immunometabolism · doi:10.20900/immunometab20190007 · Cited by 4
“However, D-2HG has been shown to destabilize Hif-1α protein by the induction of αKG-dependent prolyl hydroxylases leading to its proteasomal degradation [10].”
BackgroundAdvanced Physiologic Imaging: Perfusion – Theory and Applications
Kickingereder, P., Park, J. E., & Boxerman, J. L. (2019) · Springer eBooks · doi:10.1007/978-3-030-27359-0_5 · Cited by 4
Advances in Brain Cancer: Creating Monoallelic Single Point Mutation in IDH1 by Single Base Editing.
Shah, S. R., Quiñones‐Hinojosa, A., & Xia, S. (2019) · PubMed · Cited by 4
Zhou, X., Zheng, M., Zhao, N., Hu, Y., Yang, K., Huo, J., Liu, G., Huang, J., Chen, L., Zhou, Y., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105569 · Cited by 4
Acidic pH is a Metabolic Switch for 2-Hydroxyglutarate Generation and SignalingPreprint
Nadtochiy, S. M., Schafer, X., Fu, D., Nehrke, K., Munger, J., & Brookes, P. S. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/051599 · Cited by 4
Mutant IDH silences GSX2 to reprogram neural progenitor cell fate and promote gliomagenesisPreprint
Xiao, Y., Shi, D. D., Guo, L., Neumann, E., Levitt, M. M., Kaphle, P., Shipman, T. E., Li, H., Cai, F., Ramirez, D. M. O., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.12.667486 · Cited by 4
“IDH oncogenes also drive tumorigenesis through chromatin-independent mechanisms, including ( R )- 2HG-dependent activation of the EGLN1 prolyl hydroxylase and consequent degradation of the glial tumor suppressor HIF1 a ( 58 , 59 ).”
Mojica, C. V., Gutierrez, K. M. E., & Mason, W. P. (2025) · Future Oncology · doi:10.1080/14796694.2025.2511587 · Cited by 3
Lohmeier, J., Meinhardt, J., Radbruch, H., Reyes, M., Brenner, W., Tietze, A., & Makowski, M. R. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07520-8 · Cited by 3
“…IDH-mutant gliomas, the accumulation of the onco-metabolite (R)−2-hydroxyglutarate ((R)−2HG) enhances the activity of EGLN prolyl 4-hydroxylases [ 32], leading to increased degradation of HIF1α; this reduction in HIF1α levels is thought to suppress angiogenesis and may partially help to explain…”
Gu, W., Wang, X., Solmonson, A., Cai, L., Xiao, Y., Tasdogan, A., Franklin, J., Zhang, Y., Zhang, H., Westfall, A. K., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci197010 · Cited by 3
“Immunoblot analysis confirmed that KDM5 inhi-somewhat below the reported IC 50 for TET2 (41), which may explain why L-2HG accumulation apparently does not impact global DNA methylation in L2HGDH-deficient NPCs.”
Inhibition of Glycolysis as a Therapeutic Strategy in Acute Myeloid Leukemias
Laister, R. C., Minden, M. D., & Mak, T. W. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1393-0_38 · Cited by 3
Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation
Pasquier, F., Chahine, C., Marzac, C., & de Botton, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1792286 · Cited by 3
IDH -wildtype secondary glioblastoma arising in IDH -mutant diffuse astrocytoma: a case report
Yoon, B.-H., Park, J. S., Kang, S.-M., Kwon, N., Lee, K. S., Kim, C., & Choe, G. (2020) · British Journal of Neurosurgery · doi:10.1080/02688697.2020.1837733 · Cited by 4
Kurimoto, M., Rockenbach, Y., Kato, A., & Natsume, A. (2023) · Genes · doi:10.3390/genes14061201 · Cited by 3
CD44 is a nexus between prognosis and therapeutics for brain cancer management
Cai, L., Lv, X., Chen, Y., & Dai, X. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.109869 · Cited by 3
Wen, H., Yun, T., Xu, W. J., Choi, S. H., Kim, H., Park, C., Lee, S., Park, S. W., Lee, S. K., & Park, S. (2013) · Analytical Chemistry · doi:10.1021/ac402947a · Cited by 3
Self-citationKälin, S., & Kälin, R. E. (2016) · Energy balance and cancer · doi:10.1007/978-3-319-41677-9_7 · Cited by 3
Mouse Models of Diffuse Lower-Grade Gliomas of the Adult
Archontidi, S., Joppé, S. E., Khenniche, Y., Bardella, C., & Huillard, E. (2020) · Neuromethods · doi:10.1007/978-1-0716-0856-2_1 · Cited by 5
Strain, S. K., Groves, M. D., & Emmett, M. R. (2020) · Neuromethods · doi:10.1007/978-1-0716-0864-7_8 · Cited by 3
Imaging of Tumor Metabolism: MR Spectroscopy
Rizwan, A., & Glunde, K. (2013) · Springer eBooks · doi:10.1007/978-3-642-40412-2_8 · Cited by 3
Laurenge, A., Pugliese, P., Scuderi, S., Mathon, B., Drouiche, L., Richard, Q., Jouannet, S., Benmohamed, C., Smirnov, K., Sakr, L. H. D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.23.608811 · Cited by 3
Shah, R., Varghese, R., Anchan, H., Pai, S., Zagade, T., Oswal, M., Agarwal, S., Sood, P., Digholkar, G., Deshpande, A., et al. (2025) · Drug Development Research · doi:10.1002/ddr.70188 · Cited by 2
“Notably, 2 ‐ HG affects the prolyl oxidase activity of HIF1A regulators, leading to HIF1A stabilization or destabilization and contributing to malignant transformation (Koivunen et al. 2012).”
The crosstalk between epigenetics and metabolism in the malignant cell
Țigu, A. B., Ivancuta, A., Constantinescu, C. S., Moisoiu, V., Grăjdieru, O., Cucoreanu, C., Nistor, M., Kegyes, D., Bancos, A., Tomacinschii, V., et al. (2026) · Discover Oncology · doi:10.1007/s12672-026-05082-1 · Cited by 2
“…reported contrary findings regarding the relation between 2-HG and HIF-1a, as it was shown that IDH1 mutant glioma samples can have reduced levels of HIF-1a [160] and that the L-2-HG enantiomer could increase the activity of the EglN prolyl hydroxylase, leading to decreased HIF-1a levels [161].”
Garcia, L., Granotier-Beckers, C., Pineau, D., Sika, D., Hideg, S., Labadie, C., Cázarez, K. A., Kundnani, J., Stuani, L., Gauthier, L., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02316-9 · Cited by 2
“Glioblastoma cell lines (Gb4, Gb7, Gb21) were generated in-house [17], while oligodendroglioma lines (BT138, BT088) were obtained from collaborators [18].”
Gliomas phenocopy an inborn error of metabolism to drive neuronal activity and tumor growth
Abdullah, K. G., Miki, K., Edgar, C. K., Wu, S. A., Xiao, Y., Huang, Y.-T., Drexler, R., Krishna, S., Puliyappadamba, V. T., Tay, L. W. R., et al. (2026) · Cell · doi:10.1016/j.cell.2026.08.037 · Cited by 2
Self-citationFrank, A. R., Vandiver, F., & McFadden, D. G. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.3c00663 · Cited by 2
Ali, T. M., Usman, R., Shah, S. A., Parvez, A., Anwar, S., Muneer, Z., & Saeed, M. (2024) · Cancer Control · doi:10.1177/10732748241271714 · Cited by 6
“50 This fi nding was supported by an analysis of 288 anaplastic glioma cases.”
Hansen, L. J., Diplas, B. H., Becher, O. J., & Yan, H. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107588721.002 · Cited by 2
Self-citationAMERICAN ASSOCIATION FOR CANCER RESEARCH
(1913) · JAMA · doi:10.1001/jama.1913.04340250087035 · Cited by 2
Mitochondrial Mutations in Cancer Progression: Causative, Bystanders, or Modifiers of Tumorigenesis?
Kurelac, I., Vidone, M., Girolimetti, G., Calabrese, C., & Gasparre, G. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1824-5_10 · Cited by 2
“Interestingly, the same metabolite has been associated with inability to stabilize HIF1α, which may at least partly explain the more favorable prognosis in glioma patients carrying IDH mutations (Koivunen et al. 2012; Losman et al. 2013).”
BackgroundInfluentialSung, C.-H., Tsuang, F.-Y., Lin, C., Chan, K., Chou, W., & Wu, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-95851-5 · Cited by 3
Zhang, T., Yuan, L., Sheng, M., Chen, Y., Wang, J., & Lan, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.840394 · Cited by 1
“enzymes in human astrocytes (22) and that overexpression of EGLN3 could suppress tumor progression of glioma models by normalized glioma capillary architecture and tightly associated with hypoxic environment (23, 24).”
BackgroundA bacterial enzyme may correct 2-HG accumulation in human cancers
Yin, W. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1235191 · Cited by 1
“However, it was also reported that this oncometabolite enhances PHD2 activity in glioma models and patient samples (9).”
BackgroundThe development of a hiPSC-based platform to identify tissue-dependencies of IDH1 R132H
Mehjardi, N., Keßler, J., Sanin, A. Y., Picard, D. J., Westhoff, P., Nickel, A., Uhlmann, C., Shi, W., Steiger, H., Remke, M., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01747-w · Cited by 1
Zhang, M., Liu, Y. J., Lu, X., Du, L., He, N., Song, H., Wang, J., Gu, Y., Yang, M., Xu, C., et al. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31384 · Cited by 1
“As a structural analog of 2 ‐ ketoglutarate (2 ‐ KG), L ‐ 2 ‐ HG can inhibit the activity of numerous 2 ‐ KG ‐ dependent dioxygenases involved in a variety of biologic processes, such as histone demethylation, DNA modification, and cell differentiation (Koivunen et al., 2012; Xu et al., 2011).”
A patent review of IDH1 inhibitors (2018-present)
Liang, Q., Wen, F., Wang, P., Jiang, Y., Geng, Y., & Zha, X. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2500959 · Cited by 1
“This leads to the activation of downstream tumor-related pathways, thereby promoting tumor cell growth, invasion, angiogenesis, and metastasis [30].”
Identification of ALKBH6 as a nucleotide demethylase with a distinct substrate preference
Das, S., Rankawat, S., Shaji, U. P., Tuti, N., Shahnaz, N., Ray, S., & Anindya, R. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110638 · Cited by 1
“…concentration of 2-hydroxyglutarate (2HG) was reported to inhibit 2OG-dependent dioxygenases because 2HG is a competitive inhibitor of enzymes requiring 2OG as a cofactor, including TET DNA demethylases (TET1/2/3) (37, 38), histone lysine demethylase JmjC (39), and AlkB family of dioxygenases (40).”
Josephine, A., Kumar, S. A., Varalakshmi, S., & Rajendran, P. (2026) · 3 Biotech · doi:10.1007/s13205-026-04753-8 · Cited by 1
Prchal, J. T. (2012) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2012.10.014 · Cited by 1
“The paper published in Nature by Koivunen and colleagues in collaboration with William Kaelin’s group in Boston and others [10] clarifies the basis of this exception to the principal role of increased HIFs in tumorigenesis and provides an explanation for the aberrant metabolism associated with leukemic isocitrate dehy…”
BackgroundIsocitrate Dehydrogenase (IDH) Mutation in Gliomas
Chesnelong, C. (2015) · Springer eBooks · doi:10.1007/978-3-319-15811-2_25 · Cited by 3
“The global downregulation of the HIF1α pathway through 2HG-dependent promotion of HIF1α degradation [ 62 ], in conjunction with the silencing of LDHA, was suggested to limit the glycolytic capacity of IDH mutant cells.”
BackgroundTargeted Therapy of IDH1-Mutated Tumors
Clark, O., & Grommes, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-49864-5_10 · Cited by 1
Molecular Drivers in Chondrosarcoma
de Jong, Y., & Bovée, J. V. M. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804257-1.00004-9 · Cited by 1
The Role of MicroRNA in Regulation of Signaling Pathways in Gliomas
Kit, O. I., Vodolazhsky, D. I., Rostorguev, E. E., Porksheyan, D. H., & Panina, S. (2018) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750818010079 · Cited by 1
MRS for D-2HG Detection in IDH-Mutant Glioma
Andronesi, O. C., Batchelor, T. T., & Cahill, D. P. (2019) · Springer eBooks · doi:10.1007/978-3-030-27359-0_11 · Cited by 1
Targeting Mitochondrial Enzymes in Pancreatic Cancer
Srivani, G., Dariya, B., Alam, A., & Nagaraju, G. P. (2019) · Springer eBooks · doi:10.1007/978-981-32-9393-9_6 · Cited by 1
Huang, F., Tian, T., Wu, Y., Che, J., Yang, H., & Dong, X. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666201130102724 · Cited by 1
Wahl, D. R., & Venneti, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-61401-4_6 · Cited by 2
Dowdy, T., & Larion, M. (2026) · Methods · doi:10.1016/j.ymeth.2026.08.005 · Cited by 1
Understanding the Role of the Solid Tumour Microenvironment in Brain Tumour Progression
Richards, R. (2017) · University of Liverpool · doi:10.17638/03005579 · Cited by 1
Shukla, S. A. (2014) · Iowa State University Digital Repository (Iowa State University) · doi:10.31274/etd-180810-4245
Smith, G. (2015) · Enlighten: Theses (The University of Glasgow)
Mitochondrial Complex II in Cancer
Kľučková, K., Neužil, J., & Rohlena, J. (2014) · Springer eBooks · doi:10.1007/978-94-017-8984-4_4
Cancer-causing mutations yield their secrets
Ledford, H. K. (2012) · Nature · doi:10.1038/nature.2012.10029
An overview of current and future treatment options for adults anaplastic oligodendroglial tumors
Ducray, F., Dehais, C., Delattre, J., & POLA Network (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.928617
“2-HG competitively inhibits multiple a-ketoglutarate enzymes leading to histone and DNA hypermethylation, altered cell differentiation and activation of enzymes implicated in HIF degradation [37-39].”
BackgroundEpigenetic basis for the oncogenic potential of IDH mutations
Lü, C. (2013) · ScholarlyCommons (University of Pennsylvania)
Twenty-fifth Annual Pezcoller Symposium: Metabolism and Tumorigenesis
Kaelin, W. G., Livingston, D. M., Loda, M. F., Vousden, K. H., & Mihich, E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2445
“R2HG, in contrast with the alternative enantiomer S-2HG, potentiates, rather than inhibits, EglN and EglN loss transforms human astrocytes (1).”
BackgroundPhénotype métabolique des tumeurs associées à des anomalies du cycle de Krebs
Janin, M. (2015) · theses.fr (ABES) · doi:10.70675/c12cbd69zd09fz4fddz91dbz86f7655d32c8
American association for cancer research — AACR congress 2014
Vaccheli, E., Michels, J., Hadoux, J., & Lotz, J. (2014) · ONCOLOGIE · doi:10.1007/s10269-014-2414-y
Identification of idh1 mutation-related gene signature of glioblastoma multiforme
Zhou, Z. (2014) · Tampere University Institutional Repository (Tampere University)
A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody
Bader, A. G., Brown, D., Winkler, M., Shim, E., Livi, C. B., Rakheja, D., Tan, J. C., Benson, D. G., Parekh, V., Kho, E.-Y., et al. (2014)
Rôle de deux suppresseurs de tumeurs TET2 et P53 dans un contexte hématopoïétique
Mahfoudhi, E. (2016) · theses.fr (ABES) · doi:10.70675/f4cb068cz8085z4a5az9d43z0a573a109bcb
Prolyl Hydroxylases in fight or flight
Henze, A., de Oliveira, R. L., & Mazzone, M. (2012) · Molecular Medicine & Therapeutics · doi:10.4172/2324-8769.1000e102
Unraveling cancer metabolism through flux analysis and metabolic engineering
Tavares, L. C. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Current state of the evolving MMMN cancer progression models of cancer
Thiagalingam, S. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9780511979811.022
Balduf, H., Pepe, A., & Kirchmaier, A. L. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-6743-8_5
Metabolic rewiring in response to genetic and environmental preturbations in cancer
Hollinshead, K. E. R. (2017) · University of Birmingham Institutional Research Archive (University of Birmingham)
miR-34a as a novel regulator of TGFβ signaling in GBM
Genovese, G., Ergün, A., Shukla, S. A., Campos, B., Ghosh, P., Quayle, S. N., Rai, K., Colla, S., Wu, C., Sarkar, S., et al. (2012)
Cancer Modeling: From Optimal Cell Renewal to Immunotherapy
Alvarado, C. L. (2017) · UNM’s Digital Repository (University of New Mexico)
Mitochondria Remodeling in Cancer
Dornfeld, K. J., & Skildum, A. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-73344-9_9 · Cited by 2
Inhibition of Metabolic Enzymes as Differentiation Therapy in Acute Myeloid Leukemia
Law, J. M. (2017) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Étude du métabolisme de la glutamine dans les leucémies aiguës myéloïdes
Jacque, N. (2015) · theses.fr (ABES) · doi:10.70675/fe4cfd43zd5f1z44cez918cz100403b38b28 · Cited by 1
A twenty-year-old woman with hemoptysis.
Darazam, I. A., Fakharian, A., Shadmehr, M. B., Dorudinia, A., & Mansouri, D. (2011) · PubMed Central
Arasanz, H. (2020) · Academica-e (Universidad Pública de Navarra) · doi:10.48035/tesis/2454/41091
Copeland, R. A. (2014) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718194536.793490062
Faculty Opinions recommendation of Control of endothelial quiescence by FOXO-regulated metabolites.
Chandel, N. S. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.739855328.793585428
Morgan, B. P. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733535967.793564738
Choate, K. A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726744181.793558674
Wang, X. W. (2012) · theses.fr (ABES) · doi:10.70675/ff2a5a94z272fz449fz844bzd0227e4143b7
“(82) found recently that accumulation of R-2HG acts as an NADPH NADP+ α -Ketoglutarate Isocitrate IDH1/2”
BackgroundPrisciandaro, J. I., Zoberi, J. E., Cohen, G. N., Kim, Y., Johnson, P. B., Paulson, E. S., Song, W. Y., Hwang, K., Erickson, B. E., Beriwal, S., et al. (2022) · Medical Physics · doi:10.1002/mp.15991
Laudicella, R., Mantarro, C., Catalfamo, B., Alongi, P., Gaeta, M., Minutoli, F., Baldari, S., & Bisdas, S. (2023) · Wiley eBooks · doi:10.1002/9781119603627.ch6
Research Progress in the Relationship and Role of IDH1/2 Gene Mutation and Acute My-eloid Leukemia
戚, 栋. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1361289
The INDIGO trial: Precision medicine finally comes to glioma
Shi, D. D., & Kaelin, W. G. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad162
Metadata
- Authors
- Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., Travins, J., Weiss, S., Looper, R., Ligon, K. L., Verhaak, R. G. W., Yan, H., & Kaelin Jr, W. G.
- Affiliations
- University of Oulu (FI)
- Brigham and Women's Hospital (US)
- Duke University (US)
- Agios Pharmaceuticals (United States) (US)
- University of Calgary (CA)
- University of Utah (US)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 484-488
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3656605
- OpenAlex
- W2142898716
- Cited by
- 727
- References
- 41
- Citations by year
- 2026: 17 · 2025: 31 · 2024: 38 · 2023: 32 · 2022: 35 · 2021: 44 · 2020: 56 · 2019: 52 · 2018: 66 · 2017: 63 · 2016: 61 · 2015: 57 · 2014: 70 · 2013: 59 · 2012: 43
- FWCI
- 24.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA068490, R01CA140316)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- R-enantiomer, IDH1 mutation, IDH2 mutation, hypoxia-inducible factor, glioma, astrocyte proliferation, oncometabolites, cancer metabolism, histone demethylation, DNA hypermethylation, CpG island methylator phenotype
- MeSH terms
- Astrocytes, Cell Line, Cell Transformation, Neoplastic, Enzyme Activation, Glioma, Glutarates, Humans, Isocitrate Dehydrogenase, Nuclear Proteins, Oncogenes, Procollagen-Proline Dioxygenase, Cell Line, Tumor, Cell Proliferation, Dioxygenases, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor-Proline Dioxygenases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.